Howmet Aerospace Inc vs Eli Lilly And Co — how do they compare? Howmet Aerospace Inc trades at $225.28 (market cap $88.76B), while Eli Lilly And Co trades at $1,174.03 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 11.7× Howmet Aerospace Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Eli Lilly And Co for 93 Days on average.
| HWM | LLY | |
|---|---|---|
Market Cap | $88.76B | $1.04T |
Volume | 2,648,516 | 3,064,878 |
Sector | Industrials | Health |
52-Week High | $292.65 | $1.28K |
52-Week Low | $184.09 | $799.57 |
Typical Hold Time | 35 Days | 93 Days |
Enterprise Value | $92.86B | $1.09T |
Dividend Yield | 0.25% | 0.59% |
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $225.55, up 1.28% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue and net income are projected to grow in 2026, supported by robust demand in aerospace and defense. Analyst consensus is overwhelmingly bullish, with an 84% buy rating and a $328.10 price target, indicating significant upside potential from current levels.
The outlook for HWM is positive, driven by earnings growth and sector tailwinds, though technical indicators suggest near-term caution. Key risks include supply-chain pressures and competitive dynamics. Institutional interest remains strong, supporting the long-term investment case for shareholders focused on aerospace exposure.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →